+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Urokinase and the mechanism of osteoblastic metastases by prostate cancer



Urokinase and the mechanism of osteoblastic metastases by prostate cancer



Fibrinolysis 6(Suppl. 1): 63-69



We have examined the pathogenesis of osteoblastic metastases by attempting to identify growth factors for cells of the osteoblast phenotype which are produced by prostatic cancer tissue. In initial studies, surgical specimens of human prostate cancer (CA) and benign prostatic hyperplasia (BPH) tissue were employed as a source of prostatic tissue, and mitogenic activity for osteoblastic cells was assessed in primary cultures of fetal calvarial cells and in osteosarcoma cells. These studies identified the presence of acid stable peptide mitogens for osteoblasts in both CA and BPH. To pursue these findings, the prostate cancer cell line PC-3 was employed. Biochemical analysis of serum-free conditioned PC-3 medium, using mainly reverse-phase high pressure liquid chromatography, disclosed the presence of a mitogen for osteoblastic cells with a molecular weight of approximately 15 kDa. Amino acid sequencing indicated that this was an amino-terminal fragment of urokinase (UK). Further studies demonstrated abundant plasminogen activator activity in PC-3 conditioned medium and substantial messenger RNA encoding UK in PC-3 cells. High molecular weight (HMW) UK but not low molecular weight (LMW) UK was mitogenic and increased cell numbers in osteoblastic cultures but not in control fibroblast cultures. Specific, competitive binding of HMW but not LMW UK to osteoblastic cells was observed. These studies indicated that the mitogenic activity of UK indeed resides in the amino-terminal region. This was confirmed by demonstrating mitogenic activity for osteoblastic cells using a peptide containing the ‘growth factor domain’ of UK. In summary, these studies have shown that an amino-terminal fragment of UK produced by PC-3 cells has growth factor activity for cells of the osteoblast phenotype. UK fragments may therefore be of importance in the pathogenesis of osteoblastic metastases produced by prostatic cancer cells.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 034144099

Download citation: RISBibTeXText

DOI: 10.1016/0268-9499(92)90096-z


Related references

Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer. Molecular Medicine 6(4): 251-267, 2000

Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Research 65(18): 8274-8285, 2005

Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer. Prostate 66(15): 1573-1584, 2006

Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer 116(6): 1406-1418, 2010

Studies on the pathogenesis of osteoblastic metastases by prostate cancer. Advances in Experimental Medicine and Biology 324: 165-171, 1992

Histopathological assessment of prostate cancer bone osteoblastic metastases. Journal of Urology 180(3): 1154-1160, 2008

The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer. Cancer Growth and Metastasis 6: 61-80, 2013

Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer. Western Journal of Medicine 163(6): 577-578, 1995

Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Research 65(17): 7554-7560, 2005

Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate 73(9): 932-940, 2013

Severe hypocalcaemia associated with extensive osteoblastic metastases in a patient with prostate cancer. Netherlands Journal of Medicine 63(1): 34-37, 2005

Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. Journal of Cellular Biochemistry 91(4): 718-729, 2004

Activation of pro-urokinase and pro-PSA by hK2, a potential prostate-specific mechanism in aggressive prostate cancer. Journal of Urology 159(5 Suppl. ): 111, 1998

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clinical Cancer Research 9(1): 295-306, 2003

In vitro study of the biological basis of osteoblastic/osteoclastic bone metastases from prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 42: 226-227, 2001